Stock Buyback Is Vote Of Confidence From Genmab Board

26 Mar 2025

The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares

Genmab Office Copenhagen - close up — The Danish Biotech Has Growth In Its Sights • Source: Genmab

It has been a tough month for Genmab, with Johnson & Johnson opting out of a pact and a lawsuit landing from AbbVie, but the Danish biotech has come out fighting with the announcement of a new share buyback program.

Key Takeaways

The timing of the buyback is interesting as it comes as Genmab gets into a legal spat with partner AbbVie

Under the plan, the Copenhagen-headquartered firm may repurchase up to 2.2 million shares with a maximum value of DKK4.0bn ($578.5m)....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

12 Jun 2025

• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

11 Jun 2025

• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

11 Jun 2025

• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

11 Jun 2025

• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.